Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
166 hedge funds and large institutions have $1.34B invested in Impax Laboratories, Inc. in 2013 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 63 increasing their positions, 60 reducing their positions, and 21 closing their positions.
64% more call options, than puts
Call options by funds: $3.98M | Put options by funds: $2.43M
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
18% more capital invested
Capital invested by funds: $1.14B → $1.34B (+$205M)
5% more funds holding
Funds holding: 158 → 166 (+8)
5% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 60
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$21.2M |
| 2 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$10.4M |
| 3 |
Jennison Associates
New York
|
+$9.54M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$9.22M |
| 5 |
Renaissance Technologies
New York
|
+$7.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
-$23.3M |
| 2 |
HM
HealthCor Management
New York
|
-$22.8M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$14.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11.5M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$10.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GH
176
GAM Holding
Zurich,
Switzerland
| – | -$853K | -41,600 | Closed |
|
|
EMG
177
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$721K | -35,200 | Closed |
|
178
Axa
Paris,
France
| – | -$654K | -31,875 | Closed |
|
|
HHC
179
Hutchin Hill Capital
New York
| – | -$602K | -29,400 | Closed |
|
|
CCIA
180
Campbell & Co Investment Adviser
Baltimore,
Maryland
| – | -$383K | -18,732 | Closed |
|
|
PP
181
Paloma Partners
Greenwich,
Connecticut
| – | -$355K | -17,300 | Closed |
|
|
HI
182
HBK Investments
Dallas,
Texas
| – | -$318K | -15,486 | Closed |
|
183
First Trust Advisors
Wheaton,
Illinois
| – | -$258K | -12,625 | Closed |
|
|
DTL
184
Dynamic Technology Lab
Singapore
| – | -$245K | -11,959 | Closed |
|
|
SSG
185
Summit Securities Group
New York
| – | -$25K | -1,221 | Closed |
|
|
TRCT
186
Tower Research Capital (TRC)
New York
| – | -$13K | -657 | Closed |
|
187
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$3K | -139 | Closed |
|
IPXL Hedge Fund Activity: Q4 2013 in Review
166 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q4 2013, worth a combined $1.34B — up 18% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IPXL positions and 21 closed out — a net gain of 8 holders — while 63 added to existing stakes and 60 trimmed.
The largest buyer was OrbiMed, adding an estimated $21.2M. The largest seller was Ascend Capital, cutting an estimated $23.3M.
- 166 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q4 2013, up from 158 in Q3 2013.
- Funds reported $1.34B of Impax Laboratories, Inc. stock for Q4 2013, up 18% quarter-over-quarter.
- 29 funds opened new Impax Laboratories, Inc. positions in Q4 2013 and 21 closed out, a net change of +8 holders.
- The largest Impax Laboratories, Inc. buyer in Q4 2013 was OrbiMed, an estimated $21.2M added.
- The largest Impax Laboratories, Inc. seller in Q4 2013 was Ascend Capital, an estimated $23.3M sold.
Based on aggregated 13F filings for Q4 2013.